Tryp Therapeutics (TRYP) aims to use psychedelics in eating disorder treatment

Dr. Jennifer Miller | Principal Investigator, Tryp Therapeutics

Tryp Therapeutics Inc. (TRYP), is conducting a phase 2 clinical trial that will investigate psilocybin’s effect on hypothalamic obesity conditions. Principal Investigator Dr. Jennifer Miller is confident that psilocybin therapy will reduce appetite drive, food-related anxiety, compulsive eating, and impulsive eating by rewiring neural pathways to alleviate the underlying psychiatric issues. She is hopeful that psilocybin could treat millions of patients with a wide range of previously untreatable, chronic conditions.

PDF of article